Trulicity ® (dulaglutide)

This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information.For current prescribing information for all Lilly products, including Summaries of Product Characteristics, Patient Information Leaflets and Instructions for Use, please visit: (England, Scotland, Wales) or (Northern Ireland).

Trulicity® (dulaglutide): Effect on Heart Rate

Treatment with dulaglutide was associated with a small increase in heart rate compared with baseline.

Detailed Information

An integrated analysis showed that treatment with dulaglutide 1.5 mg and dulaglutide 0.75 mg resulted in a mean increase in HR of 2 to 4 bpm.1

Clinical trial data, based on the evaluation of the full duration of phase 2 and phase 3 clinical studies, identified sinus tachycardia as being commonly reported by patients who were treated with dualglutide, ≤1/100.1

In the phase 2 study of patients with T2DM with or without hypertension, both dulaglutide doses increased HR at 4,16, and 26 weeks.2

Dulaglutide 0.75 mg demonstrated noninferiority to placebo in LSM changes from baseline in HR at 4,16, and 26 weeks (p≤.02 for both) but dulaglutide 1.5 mg did not show noninferiority (Table 1).2

Table 1. Changes from Baseline in Heart Rate in a Phase 2 Study Evaluating Once-Weekly Dulaglutide (1.5 mg and 0.75 mg) in Patients with T2DM With or Without Hypertension2


DU 1.5 mg (n=251)

DU 0.75 mg (n=254)

PBO (n=250)

24-Hour HR (bpm)



Difference vs PBO  
(95% CI)


Difference vs PBO  
(95% CI)


Change at 4 wks




Change at 16 wks


2.8 (1.5, 4.2)


1.6 (0.3, 2.9)b


Change at 26 wks


3.5 (2.1, 4.9)


1.3 (-0.1, 2.6)b


Abbreviations: bpm = beats per minute; DU = dulaglutide; HR = heart rate; PBO = placebo; T2DM = type 2 diabetes mellitus.

a All data presented as least-square means except baseline values, which are presented as means.

b p≤.02 for noninferiority test.


1. Data on file, Eli Lilly and Company and/or one of its subsidiaries.

2. Ferdinand KC, White WB, Calhoun DA, et al. Effects of the once-weekly glucagon-like peptide-1 receptor agonist dulaglutide on ambulatory blood pressure and heart rate in patients with type 2 diabetes mellitus. Hypertension. 2014;64(4):731-737.


bpm = beats per minute

LSM = least squares mean

T2DM = type 2 diabetes mellitus

Date of Last Review: 02 November 2020

Contact Lilly

Call or Email us

If you want to ask a Medical Information question or you want to report an adverse event or product complaint you can call us or email us at

Available Mon - Fri, 10am - 4pm, excluding Bank Holidays

Or you can

Chat with Us

Click to Chat is Offline

If you have a question, you can chat online with a Lilly Medical Information professional.

Submit a request